Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash & Equivalents (2017 - 2026)

Denali Therapeutics has reported Cash & Equivalents over the past 9 years, most recently at $205.3 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 17.36% to $205.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $205.3 million through Dec 2025, up 17.36% year-over-year, with the annual reading at $205.3 million for FY2025, 17.36% up from the prior year.
  • Cash & Equivalents was $205.3 million for Q4 2025 at Denali Therapeutics, up from $91.0 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $485.7 million in Q2 2021 and troughed at $56.9 million in Q1 2025.
  • The 5-year median for Cash & Equivalents is $136.6 million (2023), against an average of $178.8 million.
  • Year-over-year, Cash & Equivalents skyrocketed 254.04% in 2021 and then tumbled 75.89% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $293.5 million in 2021, then decreased by 25.7% to $218.0 million in 2022, then crashed by 41.71% to $127.1 million in 2023, then skyrocketed by 37.65% to $175.0 million in 2024, then grew by 17.36% to $205.3 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash & Equivalents are $205.3 million (Q4 2025), $91.0 million (Q3 2025), and $141.2 million (Q2 2025).